Document:

​

Exhibit 10.2
IMMUNOME, INC.
​
AMENDED AND RESTATED NON-EMPLOYEE 
DIRECTOR COMPENSATION POLICY
​
​
Each member of the Board of Directors (the “Board”) of Immunome, Inc. (the “Company”) who is a non- employee director of the Company (each such member, a “Non-Employee Director”) will receive the compensation described in this Amended and Restated Non-Employee Director Compensation Policy (the “Policy”) for their Board service following the closing of the initial public offering of the Company’s common stock (the “IPO”).
​
The Non- Employee Director Compensation Policy (the “Original Policy”) first became effective upon the execution of the underwriting agreement in connection with the IPO (the “Effective Date”).  The Policy amends and restates, and supersedes in its entirety, the Original Policy as of July 13, 2021. The Policy may be further amended and/or restated at any time in the sole discretion of the Board or the Compensation Committee of the Board.
​
A Non-Employee Director may decline all or any portion of their compensation by giving notice to the Company prior to the date cash is to be paid or equity awards are to be granted, as the case may be.
​
Annual Cash Compensation
​
Commencing at the beginning of the first calendar quarter following the Effective Date, each Non- Employee Director will receive a cash retainer for service on the Board and committees of the Board. The annual cash retainers will be payable in arrears in four equal quarterly installments within 30 days after the end of each calendar quarter in which the service occurred, provided that the amount of such payment will be prorated for any portion of such quarter that the Non-Employee Director is not serving on the Board.
​
		1.
	Annual Board Service Retainer:

		a.
	All Non-Employee Directors: $35,000

b.Retainer for non-executive chairperson of the Board: $70,000 (in lieu of amount listed above)
​
2.Annual Committee Member Service Retainer (in addition to Annual Board Service Retainer):
		a.
	Member of the Audit Committee: $7,500

		b.
	Member of the Compensation Committee: $5,000

		c.
	Member of the Nominating and Corporate Governance Committee: $4,000

		d.
	Member of the Science and Technology Committee: $4,000

​
		3.
	Annual Committee Chair Service Retainer (inclusive of the Annual Committee Member Service Retainer):

		a.
	Chairperson of the Audit Committee: $15,000

		b.
	Chairperson of the Compensation Committee: $10,000

		c.
	Chairperson of the Nominating and Corporate Governance Committee: $8,000

		d.
	Chairperson of the Science and Technology Committee: $8,000

​
Equity Compensation
​
Equity awards will be granted under the Company’s 2020 Equity Incentive Plan or any successor equity incentive plan (the “Plan”). All stock options granted under the Policy will be nonstatutory stock options,
​
​

​

​

​
with a term of ten years from the date of grant, subject to earlier termination upon a termination of the Continuous Service (as defined in the Plan) of the Non-Employee Director and an exercise price per share equal to 100% of the Fair Market Value (as defined in the Plan) of the underlying shares of commons stock of the Company on the date of grant. Vesting schedules for equity awards will be subject to the non- employee director’s continuous service on each applicable vesting date.
​
		(a)
	Automatic Equity Grants.

​
(i)Initial Grant for New Directors. Without any further action of the Board, each person who, after the Effective Date, is elected or appointed for the first time to be a Non-Employee Director will automatically, upon the date of their initial election or appointment to be a Non-Employee Director, be granted an initial, one-time equity award of options to purchase 7,500 shares of common stock (the “Initial Grant”). Each Initial Grant will vest in equal quarterly installments following the date of grant such that the option is fully vested on the third anniversary of the date of grant, subject to the Non-Employee Director’s Continuous Service through each applicable vesting date.
​
(ii)Annual Grant. Without any further action of the Board, on the business day following each annual meeting of stockholders of the Company, commencing with the 2021 annual meeting of the stockholders, each person who is then a Non-Employee Director will automatically be granted an option to purchase 3,750 shares of common stock (the “Annual Grant”); provided, however, that if such Non- Employee Director has not served as a member of the Board for 12 months prior to the applicable annual stockholder meeting, the number of shares subject to such individual’s Annual Grant will be pro-rated based on the number of full months served on the Board, rounded to the nearest whole share. Each Annual Grant will vest in equal quarterly installments over the four quarters following the date of grant such that the option is fully vested on the first anniversary of the date of grant, (i) subject to the Non-Employee Director’s Continuous Service through each applicable vesting date and (ii) that no Annual Grant will be granted to a Non-Employee Director in the same calendar year that such person received their Initial Grant.
​
(b)Change in Control. Notwithstanding the foregoing vesting schedules, for each Non-Employee Director who remains in Continuous Service with the Company until immediately prior to the closing of a “Change in Control” (as defined in the Plan), the shares subject to their then-outstanding Initial Grant or Annual Grant that were granted pursuant to the Policy will become fully vested immediately prior to the closing of such Change in Control.
​
(c)Remaining Terms. The remaining terms and conditions of each stock option, including transferability, exercisability, termination and expiration, will be as set forth in the Company’s standard Option Agreement, in the form adopted from time to time by the Board.
​
Expenses
​
The Company will reimburse each Non-Employee Director for reasonable out-of-pocket travel expenses to cover in-person attendance at and participation in Board and committee meetings; provided, that such Non- Employee Director timely submit to the Company appropriate documentation substantiating such expenses in accordance with the Company’s travel and expense policy, as in effect from time to time.
​
Approved: September 5, 2020
Effective Date of Original Plan: October 2, 2020
Effective Date of Plan (Amended and Restated): July 13, 2021

2________________________________________________________________________

Exhibit 10.4 
​
LICENSE AGREEMENT
AMENDMENT #8
​
 
WHEREAS, effective as of December 1, 2014, and as further amended, Miromatrix Medical Inc., a corporation organized under the laws of the State of Delaware and having an office 10399 West 70th Street, Eden Prairie, MN 55344 (“Miromatrix”) and Mayo Foundation for Medical Education and Research, a not for profit corporation with an address at 200 First Street SW, Rochester, MN 55905 (“Mayo”) executed a License Agreement (the “Agreement”) for Services as outlined in the Agreement.
 
WHEREAS, Miromatrix and Mayo wish to amend said Agreement.
 
NOW, THEREFORE, Miromatrix and Mayo agree as follows:
 
		1.	Miromatrix has agreed to provide additional funding of $75,608 for expansion to include more control animals for additional experiments.  Accordingly, the attached Exhibit B-5 shall amend Section 3 of the Agreement.

​
		2.	Except as specifically provided herein, the terms and conditions of the Agreement shall remain in force.

​
IN WITNESS WHEREOF, the Parties have executed this Amendment which shall be effective as of the last dated signature below.
​
MIROMATRIX MEDICAL INC.MAYO FOUNDATION FOR MEDICAL
EDUCATION AND RESEARCH       
​
​
By: ​ ​/s/ Jeff Ross​ ​​ ​​ ​​ ​By: ​ ​/s/ Randall S. Jones​ ​​ ​​ ​
Name: ​ ​Jeff Ross​ ​​ ​​ ​​ ​Name: ​ ​Randall S. Jones​ ​​ ​​ ​
Title: ​ ​CEO​ ​​ ​​ ​​ ​​ ​Title: ​ ​Operations Manager​ ​​ ​​ ​
Date: ​ ​7/5/2021​ ​​ ​​ ​​ ​Date: ​ ​6/30/2021​ ​​ ​​ ​​ ​
​
 
​

​
Budget – Exhibit B-5
​​

Exhibit 10.5
Employee CONFIDENTIALITY, 
NON-COMPETITION, AND NON-SOLICITATION AGREEMENT
This Employee Confidentiality, Non-Competition, and Non-Solicitation Agreement (this “Agreement”) is entered into as of the date of the execution of this Agreement and is effective as of _____________, 202___ (the “Effective Date”), by and between Miromatrix Medical Inc., (“Company”), and _______________ (“Employee”).
For good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows:
	1.   
	Definitions 

1.1   “Confidential Information” means all nonpublic or proprietary information (in tangible or intangible form) arising from, relating to or in the possession of Company or any of its affiliates, Company’s or any of its affiliates’ business, or any Customer (defined below) of Company or any of its affiliates, including, but not limited to: software (in source or object code form), databases, algorithms, processes, designs, prototypes, methodologies, specifications; reports; information regarding products sold, distributed or being developed or regarding current and developing technology; information regarding vendors, customers, prospective customers, clients, and business contacts; prospective and executed contracts and subcontracts; marketing plans, sales plans, or any other plans and proposals developed or used by Company; information relating to Company’s present or future business plans; financial and accounting information; and information concerning Company Inventions. 
1.2   “Company Inventions” means any or all of the following and all statutory and/or common law rights throughout the world in, arising out of, or associated therewith: (i) all ideas, methodologies, processes, inventions (whether patentable or not), discoveries, modifications, improvements, know how and technology; (ii) all works of authorship, copyrights, mask works, and applications and registrations therefor; (iii) all patents and applications therefor and all reissues, divisions, renewals, extensions, provisionals, substitutions, continuations and continuations-in-part thereof; (iv) all designs and any registrations and applications therefor; (v) all trade names, logos, trademarks and service marks, and applications and registrations therefor and all goodwill associated with any of the foregoing; (vi) all databases and data collections (including, but not limited to) knowledge databases; (vii) rights to uniform resource locators, web site addresses and domain names; (viii) all moral rights; (ix) Confidential Information, (x) any equivalent rights to any of the foregoing; and (xi) all rights to enforce any of the foregoing rights, including the right to sue for past damages that directly or indirectly arise from or relate to: 
(a) Company’s business, technology, products, software, or services; 
(b) work or research performed for Company by Employee or any other Company officer, employee, agent, contractor or subcontractor; 
(c) the use of Company’s products, scientific methods, technology, equipment, software, or time; or 
(d) access to Confidential Information.
1.3    “Competing Business” means a business which competes or is reasonably likely to compete with any business (i) which the Company conducts or proposes to conduct at any time during Employee’s service with the Company or (ii) any other business which the Company or any of its affiliates conducts or proposes to conduct, if Employee participated in the conduct of or planning for such business.
1.4    “Customer” means any present or past vendor, supplier, investor, customer, or business partner of the Company or any prospective vendor, supplier, investor, customer, or business partner of the Company with whom Employee has had contact during Employee’s service with the Company.
1.5    “Solicit” means to, directly or indirectly: (i) solicit the business or patronage of any Customer for any Competing Business; (ii) divert, entice, or otherwise take away from the Company the business or patronage of any Customer, or attempt to do so; or (iii) solicit or induce any Customer to terminate or reduce its relationship with the Company.

​

​

1.6    “Territory” means: (i) all counties in the State of Minnesota; (ii) all other states of the United States of America; and (iii) all other countries of the world in which the Company does business at any time prior to the date of the termination of Employee’s relationship with the Company. 
1.7   “Restricted Period” means a period of twelve (12) months immediately following the termination of Employee’s employment or engagement by the Company for any reason or no reason, whether with or without cause or for any or no reason, at the option of either Company or Employee, with or without notice.
	2.   
	Confidential Information.

2.1   Employee’s Use of Confidential Information.  Employee will at all times during and after this Agreement, maintain the confidentiality of the Confidential Information.  Not limiting the foregoing, Employee will not, without Company’s prior written consent, directly or indirectly: (i) copy or use any Confidential Information for any purpose not within the scope of Employee’s current work for Company; or (ii) show, give, sell, disclose or otherwise communicate any Confidential Information to any person or entity other than Company unless such person or entity is authorized by Company to have access to the Confidential Information in question. These restrictions do not apply if the Confidential Information has been made generally available to the public by Company or becomes generally available to the public through some other proper course of events.  All Confidential Information prepared by or provided to Employee are and will remain Company’s property or the property of Company’s customer to which they belong.  Notice of Immunity under Defend Trade Secrets Act of 2016, 18 U.S.C. § 1833(b):  Notwithstanding any other provision of this Agreement or any policy of the Company, Employee will not be held criminally or civilly liable under any federal or state trade secret law for the disclosure of a trade secret that is made (a) in confidence to a federal, state, or local government official, either directly or indirectly, or to an attorney if such disclosure is made solely for the purpose of reporting or investigating a suspected violation of law or for pursuing an anti-retaliation lawsuit or (b) in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal and Employee does not disclose the trade secret except pursuant to a court order.
2.2   Former Employers’ Confidential Information.  Employee will not improperly use or disclose to Company or any Company employee, agent or contractor any confidential or proprietary information (including the substance of any unpublished patent applications or invention disclosures) belonging to any former employer of Employee or any other person or entity to which Employee owes a duty of nondisclosure
2.3   Return of Material.  Upon request of Company or upon termination (whether voluntary or involuntary), Employee will immediately turn over to Company all Confidential Information, including all copies, and other property belonging to Company or any of its customers, including documents, disks, or other computer media in Employee’s possession or under his/her control.  Employee will also return any materials that contain or are derived from Confidential Information, or are connected with or relate to Employee’s services to Company or any of its customers.
	3.   
	Company Inventions.

3.1   Disclosure of Company Inventions.  Employee will promptly disclose to Employee’s supervisor and Company, or its designee, all Company Inventions that Employee has made, discovered, conceived, reduced to practice, or developed, contributed to or knows about, regardless of the nature of that knowledge, and regardless of whether such Company Invention, or any aspect of such Company Invention, has been described, committed to writing, or reduced to practice, in whole or part, by any other person.    
3.2   Assignment of Inventions; Waiver of “Moral Rights”.  All Company Inventions created by Employee (solely or jointly with others) that are “works made for hire” (as that term is defined by applicable law) are owned by Company.  To the extent that any Company Inventions are not owned by the Company by operation of law, Employee hereby assigns to Company all right, title, and interest in and to such Company Inventions.  To the extent moral rights are not permitted to be assigned to Company by law, Employee hereby irrevocably waives, to the extent permitted by law, all rights under all laws (of the United States and all other countries) now existing or hereafter in effect, with respect to any and all Company Inventions, including without limitation: (i) all rights under the United States Copyright Act, or any other country’s copyright law, including 

​

​

but not limited to, any rights provided in 17 U.S.C. §§ 106 and 106A; and (ii) any rights of attribution and integrity or any other “moral rights of authors” existing under statutory, common or any other law.  The consideration for such assignment, waiver and the assistance required in this Section 3.3 and Section 3.4, is the normal compensation paid to Employee by virtue of his/her service to Company.  
3.3   Additional Assistance. At no additional cost, whether during or after Employee’s employment with Company, Employee will promptly execute and deliver to Company all additional instruments or documents and perform any acts reasonably requested by Company to assist it in evidencing, obtaining, maintaining, defending and enforcing any rights and/or assignment of a Company Invention.  Employee hereby irrevocably designates and appoints Company and its duly authorized officers and agents, as Employee’s agent and attorney-in-fact to act for and on Employee’s behalf and instead of Employee, to execute and file any documents or applications or to do all other lawfully permitted acts in furtherance of the purposes set forth above in this paragraph, including, without limitation, the perfection of assignment and the prosecution and issuance of patents, patent applications, copyright applications and registrations, trademark applications and registrations, or other rights in connection with such Company Inventions and improvements thereto with the same legal force and effect as if executed by Employee. 
3.4   Pre-existing Inventions.  Employee has listed on Schedule 1 all inventions and works of authorship related to Company’s business, that Employee created prior to employment with Company.  If Schedule 1 is left blank, Employee warrants that no such pre-existing inventions exist.  Except as provided herein, as between Employee and Company, Employee will retain all right, title and interest in and to such inventions and works of authorship.  Employee will promptly disclose to Company any modifications or improvements to any such prior inventions or works of authorship that fall within the definition of Company Invention (and assigns rights thereto to Company pursuant to Section 3.2).  In the event Employee, during the course of or resulting from employment with Company, uses, develops, or otherwise provides Confidential Information, Company Inventions or other works that incorporate or reasonable require the use any of Employee’s prior inventions or works of authorship, Employee hereby grants Company an unrestricted, royalty-free, perpetual, irrevocable, transferable license to make, have made, use, market, import, distribute, copy, modify, prepare derivative works, perform, display, disclose, sublicense and otherwise exploit any and all such inventions and works of authorship. 
4.   Use of Company Equipment.  Employee will not use any of the Company’s equipment or facilities for any purpose other than in connection with the performance of services on behalf of the Company unless Employee receives prior written authorization from the Company.
	5.   
	Restrictive Covenants.   

5.1   Non-Solicitation of Customers.   During Employee’s employment with (or other affiliation with) Company and for the duration of the Restricted Period, Employee will not Solicit.
5.2    Non-Solicitation of Company Employees. During Employee’s employment with (or other affiliation with) Company and for the duration of the Restricted Period, Employee will not, directly or indirectly: (i) encourage or solicit any employee or consultant who worked for Company on the date of Employee’s termination to leave Company for any reason, nor will Employee solicit such person’s services; (ii) assist any other person or entity in such encouragement or solicitation; or (iii) otherwise interfere with the relationship any employee or consultant has with Company.
5.3   Non-Competition.  In order to protect Confidential Information, which would cause irreparable harm to Company if disclosed in violation of this Agreement, while employed by (or otherwise affiliated with) Company and for the duration of the Restricted Period, Employee will not, in every part of the Territory, without the prior written consent of Company: (i) serve as a partner, employee, consultant, officer, director, manager, agent, associate, investor, or otherwise for; (ii) directly or indirectly, own, purchase, organize or take preparatory steps for the organization of; or (iii) build, design, finance, acquire, lease, operate, manage, invest in, work or consult for or otherwise affiliate with: (a) any Competing Business, (b) any business that is otherwise similar to the Company’s business, or (c) any business that inevitably will result in the disclosure or use of Confidential Information.  The covenants contained in this subsection will 

​

​

be construed as a series of separate covenants, one for each city, county and state of any geographic area in the Territory.  If, in any judicial proceeding, a court refuses to enforce any of such separate covenants (or any part thereof), then such unenforceable covenant (or such part) will be eliminated from this Agreement to the extent necessary to permit the remaining separate covenants (or portions thereof) to be enforced.  
5.4   Certain Acknowledgements by Employee.  Employee acknowledges that: (i) Employee will derive significant value from the Confidential Information that Company will provide to Employee in order to enable Employee to optimize the performance of Employee’s duties to Company, and Employee will occupy a position of trust and confidence with Company; (ii) Employee’s fulfillment of the obligations contained in this Agreement are reasonable and necessary to protect the Confidential Information and the value and goodwill of the Company; (iii) Employee will not be precluded from gainful employment if obligated not to compete with the Company during the period specified in subsection 5.3 within the Territory as described above; and (iv)  Company would be irreparably damaged if Employee were to provide services to any person or entity in violation of the provisions of this Agreement.
5.5   Duration of Covenant.  If Employee violates any covenant contained in this Section 5, the duration of such covenant so violated will be automatically extended for a period of time equal to the period of such violation.
6.   Supplemental Agreements and Policies.  Without limiting Employee’s obligations set forth herein, Employee will comply with Company’s then current policies and procedures (including, but not limited to, policies and procedures relating to Confidential Information).
7.   Survival.  Employee’s obligations under this Agreement will survive the termination of Employee’s employment with Company regardless of the reason for the termination and whether the termination was voluntary or involuntary on the part of the Employee.  Company is entitled to communicate Employee’s obligations under Sections 2, 3 and 5 to Employee’s future or potential employer.
8.   Remedies.  Each of the rights and remedies enumerated herein is independent of the other, and will be severally enforceable, and such rights and remedies will be in addition to, and not in lieu of, any other rights and remedies available to the Company under law or equity.  In the event of any breach of any obligation under this Agreement, including obligations of confidentiality, non-solicitation, non-competition and disclosure of inventions, Company will suffer immediate and irreparable harm and damage and will not have an adequate remedy at law.  Upon any such breach or threatened breach, in addition to any and all legal remedies, Company will be entitled to obtain injunctive and all other appropriate relief from a court of competent authority in order to prevent or restrain any such breach or threatened breach by Employee or by Employee’s partners, agents, representatives, servants, employees, and/or any and all persons directly or indirectly acting for Employee, without being required to: (i) show any actual damage or irreparable harm; (ii) prove the inadequacy of its legal remedies; or (iii) post any bond or other security.  This Section may not be construed as an election of any remedy or as a waiver of any right available to Company under this Agreement or the law, including the right to seek damages from Employee for a breach of any provision of this Agreement.
9.   Entire Agreement.  This Agreement, the Schedule attached hereto and all supplemental agreements and policies pursuant to Section 6 sets forth the entire agreement between the parties and supersedes any and all prior agreements or representations, written or oral, of the parties with respect to the subject matter of this Agreement.  In the event of any conflict between any term of this Agreement and any term of any other agreement either written or oral, the terms of this Agreement will control, unless explicitly stated otherwise in the subsequent agreement.  If Employee signed or signs any other agreement(s) relating to or arising from Employee’s service to or employment with Company, provisions of such agreement(s) that do not directly conflict with a provision of this Agreement will not be affected, modified or superseded by this Agreement, but rather will remain fully enforceable according to their terms.
10.   Modification.  This Agreement can only be modified by a subsequent written agreement executed by Employee and a duly authorized officer of Company.
11.   Heirs and Assigns.  In light of the unique personal services to be performed by Employee hereunder, any purported or attempted assignment or transfer by Employee of this Agreement or any of Employee’s 

​

​

responsibilities or obligations hereunder will be void. The assignment and waiver of rights under this Agreement are irrevocable and binding on Employee’s heirs and assigns. Company in its sole discretion may assign this Agreement to any parent, subsidiary, affiliate or successor of Company without prior written consent of Employee.
12.   Governing Law and Venue.  The validity, enforceability, construction and interpretation of this Agreement are governed by the laws of the State of Minnesota.  In the event a dispute arises regarding this Agreement, the parties will submit to the jurisdiction of the federal and state courts of the State of Minnesota.  Employee expressly waives any objection as to jurisdiction or venue in the state and federal courts located in Hennepin County, Minnesota.
13.   Severability.  Subject to Section 5.3, if any court of competent jurisdiction declares any provision of this Agreement invalid or unenforceable, the remainder of this Agreement will remain fully enforceable.  To the extent that any court concludes that any provision of this Agreement is void or voidable, the court will reform such provision(s) to render the provision(s) enforceable, but only to the extent absolutely necessary to render the provision(s) enforceable and only in view of the parties’ express desire that Company be protected to the greatest extent allowed by law from unfair competition and/or the misuse or disclosure of Confidential Information and/or Company Inventions.
14.   At-Will Employment.  THIS AGREEMENT IS NOT A GUARANTEE OR PROMISE OF EMPLOYMENT FOR A DEFINITE PERIOD OF TIME, AND EMPLOYEE’S EMPLOYMENT WITH COMPANY IS “AT-WILL” AND MAY BE TERMINATED BY EITHER PARTY AT ANY TIME, WITH OR WITHOUT CAUSE AND WITH OR WITHOUT NOTICE.
Employee has carefully read and considered all provisions of this Agreement and acknowledges that all of the restrictions set forth herein are fair and reasonable and reasonably required to protect Company’s interests.
​
IN WITNESS WHEREOF, the parties have caused this Agreement to be executed by their duly authorized representatives, on the Effective Date above.
​
Employee      MIROMATRIX MEDICAL INC.
	​
Signature:  ____​ ​​ ​​ ​​ ​​ ​
Print name:  ​ ​​ ​​ ​​ ​​ ​
Date:  ​ ​​ ​​ ​​ ​​ ​​ ​
​
	​
By: ​ ​​ ​​ ​​ ​​ ​​ ​
Print Name:  ​ ​​ ​​ ​​ ​​ ​
Title:  ​ ​​ ​​ ​​ ​​ ​​ ​
Date:  ​ ​​ ​​ ​​ ​​ ​​ ​

​
​
​​

​

​

SCHEDULE 1
Pre-Existing Inventions

​

​

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00336-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00336-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00336-of-00352.parquet"}]]